Journal article
Safety of human papillomavirus vaccines: A review
KK Macartney, C Chiu, M Georgousakis, JML Brotherton
Drug Safety | ADIS INT LTD | Published : 2013
Abstract
Vaccination to prevent human papillomavirus (HPV)-related infection leading to cancer, particularly cervical cancer, is a major public health breakthrough. There are currently two licensed HPV vaccines, both of which contain recombinant virus-like particles of HPV types 16 and 18 (which account for approximately 70 % of cervical cancer). One vaccine also protects against HPV types 6 and 11, which cause genital warts. The safety profile of both vaccines was assessed extensively in randomised controlled clinical trials conducted prior to licensure and has been further elucidated following licensure from surveillance and specific studies in large populations. This review aims to examine current..
View full abstractGrants
Funding Acknowledgements
Associate Professor Macartney, Dr. Clayton Chiu and Dr. Melina Georgousakis are employees of the Australian National Centre for Immunisation Research and Surveillance, which receives funding from the Australian Government Department of Health and Ageing and the New South Wales Department of Health. Dr. Brotherton is an employee of the Victorian Cytology Service (VCS), which receives funding from the Victorian Health Department and the Australian Government Department of Health and Ageing.